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Effects of C-peptide on renal function at the early stage of
experimental diabetes.
Background. C-peptide has been reported to have biological
effects on renal function early in the course of diabetes. This
investigation was initiated to elucidate and amplify these findings
with respect to protein leakage, hyperfiltration and renal func-
tional reserve in diabetic rats.
Methods. Acute effects of 140 minutes i.v. infusion of human
C-peptide (0.5 nmol z min21 z kg21 body wt) on renal function and
urinary protein leakage were studied in anesthetized diabetic male
rats two weeks after streptozotocin injection without insulin
treatment. Streptozotocin-induced diabetic rats were studied with
(N 5 6) and without C-peptide (N 5 11) treatment. The two
groups showed a similarly elevated blood glucose concentration
during the study. Age-matched normal rats served as controls
(N 5 5). Glomerular filtration rate (GFR) was measured by inulin
clearance in the basal state and during a 60-minute glycine
infusion (0.22 mmol z min21 z kg21 body wt)–resembling a protein
load challenge–to test the renal functional reserve in all three
groups.
Results. In the basal state, the non-C-peptide-treated diabetic
rats displayed increased GFR and increased total protein leakage
compared with normal rats. Whereas normal rats responded to
glycine infusion with an increase in GFR, no increase occurred in
diabetic rats not treated with C-peptide. In diabetic rats given
C-peptide, this reduced the initial glomerular hyperfiltration prior
to glycine infusion. This indicates a specific effect, since a control
peptide with the same amino acid composition as C-peptide, but
in a randomized sequence, had no such effect. C-peptide also
restored half of the normal renal functional reserve and resulted
in 70% lower (P , 0.05) total protein leakage compared with that
in rats not given C-peptide.
Conclusion. Thus, short-term infusion of C-peptide had bene-
ficial effects on protein leakage and hyperfiltration and improved
the renal functional reserve in rats with experimental diabetes.
Glomerular hyperfiltration is a common finding in pa-
tients with type 1 diabetes, particularly during the early
phase of the disease [1, 2]. The increased glomerular
filtration rate (GFR) may persist for several years, possibly
until the development of diabetic nephropathy. The mech-
anisms underlying this diabetic complication are complex
and probably multifactorial. It has been speculated that an
early increase in intraglomerular pressure associated with
changes in vascular permeability is the major cause of the
glomerulopathy [3].
A low renal functional reserve (RFR), which means a
partial or total inability to increase glomerular filtration
during a protein load, has been suggested as a valid index of
hyperfiltration [4]. The reason for a low RFR in diabetes
seems to be that the intraglomerular pressure and flow are
already elevated in this state, thus preventing a further
increase in GFR. RFR measurements will reveal early
renal dysfunction before the appearance of any diabetic
nephropathy [5].
C-peptide, the connecting peptide chain of the proinsulin
molecule, is released from the pancreatic b-cell into the
circulation together with insulin in equimolar amounts [6].
Type 1 diabetes is characterized by progressive destruction
of the pancreatic b-cells, leading to insufficient or totally
abolished secretion of both insulin and C-peptide. C-
peptide has been considered to be a biologically inert
substance [6]. However, in a clinical study, Johansson and
co-workers have recently found that both short- and long-
term infusions of C-peptide reduced glomerular hyperfil-
tration and albumin excretion in young patients with type 1
diabetes [7, 8]. To further evaluate and confirm the effects
of C-peptide on the early changes in renal function caused
by the diabetic state, we chose an experimental rat diabetes
model. The glomerular filtration rate was studied in rats
with STZ-induced diabetes under both basal conditions and
during amino acid infusion. On the basis of experimental
evidence suggesting a close link between proteinuria and
hyperfiltration [9], we have also studied the effect of
C-peptide on renal protein excretion.
The aim of this investigation was to use an experimental
model in which the biological effects of C-peptide could be
tested on early abnormalities of the kidney due to diabetes.
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Such a model is necessary for further investigations con-
cerning the role of C-peptide in the etiology of renal
dysfunction in diabetes mellitus. One specific aim of the
present study was to determine whether C-peptide exerts
its actions as a hormone or whether its effects are “chem-
ical” due to its amino acid composition. This was tested by
using a “scrambled C-peptide.”
METHODS
Diabetes was induced in male Sprague-Dawley rats
(Møllegaard, Copenhagen, Denmark; age 8 weeks, initial
body wt about 200 g) by i.v. injection of 40 mg/kg body wt
streptozotocin (STZ). Age-matched rats served as a control
group.
Before the experiments, all animals had free access to tap
water and standardized chow (R3, Ewos, So¨derta¨lje, Swe-
den) containing 3 g Na/kg, 8 g K/kg and 13 megajoule/kg.
For two days per week, all rats were put in metabolic cages
(Tecniplast Gazzada 3701MO-000, Buguggiate, Italy).
Their body weights, daily intake of food and water, and
excretion of urine and feces were measured individually.
Metabolic data were obtained before and after the STZ
injection.
General surgical procedures
In the third week all rats were anesthetized by intraperi-
toneal injection of Inactin® (sodium 5-sec-butyl-5-ethyl-2-
thiobarbiturate; Byk-Gulden, Konstanz, Germany), 120
mg/kg body wt, and placed on a servo-controlled heating
pad to maintain the body temperature at about 37.5°C.
A cannula was inserted into the trachea to facilitate
spontaneous breathing. The left femoral vein was cannu-
lated for continuous infusion (5 ml z hr21 z kg21 body wt) of
a Ringer solution containing (in mM) 129 NaCl, 2.5 KCl, 25
NaHCO3 and 0.75 CaCl2. The Ringer solution contained 4
mg/ml fluorescein isothiocyanate (FITC) labeled inulin
(Pharmacia AB, Uppsala, Sweden), following a bolus injec-
tion of 4 mg FITC-inulin in a volume of 1 ml. This solution
also served as a vehicle when C-peptide and glycine were
infused. The left femoral artery was cannulated for contin-
uous recording of the mean arterial blood pressure (MAP)
and for blood sampling. The bladder was catheterized
through a suprapubic incision.
Experimental protocol
Three groups of rats were studied: (1) normal age-
matched rats; (2) rats with STZ-induced diabetes (STZ-D);
(3) STZ-D rats treated with C-peptide (STZ-D C-peptide
group). In the latter group, biosynthetic human C-peptide
(Eli Lilly, Indianapolis, IN, USA) was used. This peptide
was dissolved in the Ringer’s solution and given immedi-
ately at the end of surgical preparation, as an initial bolus
injection of 6 nmol in a volume of 1 ml followed by
continuous infusion at a rate of 0.5 nmol z min21 z kg21
body wt throughout the experiment. All rats were allowed
a 60-minute period of rest after surgery. Urine samples
were then collected for 80 minutes at 10 minute intervals.
Thus, C-peptide was infused for a total time period of 140
minutes. Plasma samples (; 60 ml) were taken at the
midpoint of each urine collection period. Glycine was
infused intravenously (0.22 mmol z kg21 z min21) in all three
groups after two basal collections, and MAP, GFR (mea-
sured with FITC-inulin) and renal fluid and electrolyte
excretion were studied throughout the experiment.
To assess the specificity of C-peptide, an additional
experiment was performed. A “scrambled C-peptide” (Fer-
ring AB, Malmo¨, Sweden) was infused at the same rate as
that for C-peptide described above. This “scrambled pep-
tide” was synthesized with the same amino acid composi-
tion as C-peptide but with the order randomized. In the
additional experiments three groups of rats were examined:
(1) STZ-D rats infused with saline (N 5 5); (2) STZ-D rats
infused with C-peptide (STZ-D C-peptide group, N 5 6);
(3) STZ-D rats infused with scrambled peptide (STZ-D
scrambled peptide group, N 5 5). The experiments were
designed as described above with the exception that the
infusion of C-peptide started 90 minutes after the surgical
procedure and continued for 60 minutes, the urine collec-
tions were started 30 minutes earlier to reveal the onset of
the effects of the peptides, and that the glycine infusion was
not given.
C-peptide determination
At the end of each experiment, 2 ml of arterial blood was
collected in ice-cold tubes containing 5% Na2EDTA and
then immediately centrifuged at 1100 g and 4°C for 15
minutes. The plasma was withdrawn and stored at 270°C.
The C-peptide concentration in plasma was measured by
radioimmunoassay using a commercial kit (C-peptide RD
315; MILAB, Malmo¨, Sweden). The antibody used has no
cross-reactivity with rat C-peptide. The assay sensitivity was
0.1 nmol z l21.
FITC-inulin determination
The technical details have been described in a previous
report [10]. In brief, standards, urine samples and plasma
samples were transferred to constant-bore capillaries (0.5
ml; Microcaps, Drummond, USA) and analyzed for FITC-
inulin in a Ploemopak fluorescence microscope (Leitz
Dialux 22 EB, Germany) equipped with a photometer
(Leitz MPV compact, Germany). Measurements were
made from the central portion of the sample.
Urine analysis
Urine volumes were measured gravimetrically. Urinary
sodium and potassium concentrations were determined by
flame photometry (IL 543; Instrumentation Lab., Milano,
Italy). The osmolality was measured by the freezing point
depression method (Model 3MO; Advanced Instruments,
MA, USA).
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Urine protein assay
Urine protein concentration was measured colorimetri-
cally using the Coomassie® protein assay method (Pierce,
Rockford, USA). The assay sensitivity was 2.5 mg/ml, the
intraassay coefficient of variation (cv) was 7.8% and the
interassay cv was 10.5%.
Blood glucose measurement
Once a week before and after STZ injection, the blood
glucose concentration (sampling from the tip of the tail of
each rat) was determined by means of Accutrend® (Boehr-
inger Mannheim GmbH, Mannheim, Germany). At the
end of the acute experiments, the arterial plasma glucose
concentration was measured with the glucose oxidase
method (Glucose analyzer 2; Beckman, Brea, CA, USA).
Statistics
All data are presented as means 6 SEM. The effects of
glycine infusion on renal function were tested by analysis of
variance (ANOVA) with a repeated measures design,
followed by the TUKEY post hoc test applied within each
group. Comparisons between groups were made with
ANOVA followed by the t-test. T values were Bonferroni
adjusted when necessary. A P value of less than 0.05 was
considered to be statistically significant.
RESULTS
The results obtained from individual metabolic cages are
shown in Table 1. The control rats and the STZ-D rats had
similar initial body wts and consumed similar amounts of
water and food. Two weeks after injection of streptozoto-
cin, the control rats and the STZ-D rats showed significant
differences in body wt and in water and food intake. The
reduced growth rate and elevated blood glucose concentra-
tion in the STZ-D rats indicated that they had developed
diabetes mellitus. The consumption of water and food in
this group of rats showed the presence of polydipsia and
polyphagia. Fourteen days after the STZ treatment the
STZ-D rats exhibited significant increases in urine flow rate
and urinary protein excretion rate as compared with the
controls (Table 1). At the same time the electrolyte excre-
tion rate also increased in these rats. The rate of potassium
excretion tended to increase more than that of sodium
excretion in the STZ rats, resulting in a slightly reduced
urinary sodium to potassium ratio (from 0.55 6 0.06 to
0.37 6 0.35).
During the renal functional studies, the basal GFR was
higher (120%, P , 0.05) in the non-C-peptide treated
STZ-D rats than in the controls. This was not the case in
the STZ-D rats receiving C-peptide; their mean GFR value
was 20% lower than that in the non-C-peptide treated
STZ-D rats and hence not different from that in the normal
rats. Thus, C-peptide normalized the hyperfiltration found
in the STZ-D rats (Fig. 1). During the glycine infusion
period, GFR increased by 70% (P , 0.05) in the normal
rats and by 35% (P , 0.05) in the C-peptide treated STZ-D
rats. However, the STZ-D rats not treated with C-peptide
showed no change in GFR during glycine infusion, illus-
trating a loss of RFR (Fig. 1). Thus, C-peptide partly
restored the GFR response to glycine in the STZ-D rats.
Glycine infusion also caused a marked, rapid, but transient
rise in MAP in the normal rats (from 126 6 5.1 to a
maximum of 145 6 3.5 mm Hg, P , 0.05), but not in the
non-C-peptide treated STZ-D rats (before infusion, 112 6
4.2; after infusion, 113 6 5.0 mm Hg). However, the
C-peptide treated STZ-D rats displayed a response to
glycine infusion similar to that in the normal rats, with a
rise in MAP from 112 6 5.3 to a maximum of 127 6 5.3 mm
Hg (P , 0.05; Fig. 2). The initial urine flow rate in the
STZ-D rats was higher and the urine osmolality lower than
in the normal rats. During glycine infusion, the normal rats
showed a significant (P , 0.01) increase in urine flow and
a reduction in urine osmolality, while the non-C-peptide
treated STZ-D rats did not. However, the C-peptide
treated STZ-D rats increased their urine flow rate in
response to glycine infusion (P , 0.05) (Fig. 3). During
glycine infusion the normal rats displayed a much higher
increase in the potassium excretion rate (UKV˙) than the
two STZ-D groups (ANOVA, P , 0.01) and no difference
was found between STZ-D rats treated and not treated with
Table 1. Mean values 6 SEM of metabolic parameters one day before (day 21) and two weeks after (day 14) STZ treatment in the age-matched
control animals (Control, N 5 8) and the animals with streptozotocin-induced diabetes (STZ-D, N 5 8)
Group
Days from
STZ (day 0)
Control
21
STZ-D
21
Control
14
STZ-D
14
Blood glucose mM 6.9 6 0.3 NS 6.7 6 0.2 4.8 6 0.5 p , 0.01 19 6 0.8
Body wt g 207 6 3 NS 210 6 3 324 6 4 p , 0.01 230 6 7
Water intake ml/day 34 6 2 NS 31 6 3 35 6 1 p , 0.01 213 6 8
Food intake g/day 22.1 6 0.8 NS 21 6 0.6 25.9 6 0.5 p , 0.01 40.8 6 1.2
V˙ ml/day 11.9 6 1.5 NS 10.3 6 1.4 12.7 6 0.8 p , 0.01 180.3 6 6.1
UProteinV˙ mg/min 4.2 6 0.4 NS 4.5 6 0.3 8.2 6 0.7 p , 0.01 36.3 6 11.0
UNaV˙ mmol/day 1.4 6 0.1 NS 1.4 6 0.1 1.6 6 0.1 p , 0.05 2.5 6 0.2
UKV˙ mmol/day 2.3 6 0.1 NS 2.5 6 0.2 3.3 6 0.2 p , 0.01 6.2 6 0.4
Abbreviations are: body wt, body weight; (V˙), urine flow rate; UProteinV˙, urinary protein excretion rate; UNaV˙, sodium excretion rate; UKV˙, potassium
excretion rate.
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C-peptide. This was not the case for the sodium excretion
rate (UNaV˙), indicating more pronounced impairment of
the kaliuretic than of the natriuretic response during
glycine administration in the STZ-D rats. UNaV˙ was signif-
icantly higher in the STZ-D C-peptide group than in the
STZ-D group (unpaired t-test, P , 0.05) during the period
20 to 60 minutes from the start of the experiment (Fig. 4).
C-peptide seems to be capable of increasing the sodium
rather than the potassium excretion rate, resulting in an
increased sodium to potassium excretion ratio.
In the anesthetized rats prior to glycine infusion, the
urinary protein excretion rate in C-peptide treated STZ-D
rats was 3.1 6 0.7 mg/min, whereas in the STZ-D rats not
receiving C-peptide it was 13.0 6 2.9 mg/min (P , 0.05).
Thus, it seems that C-peptide restored the diabetic protein-
uria to the value seen in the normal rats (5.4 6 1.5 mg/min).
The concentration of human C-peptide in plasma was
zero both in the normal age-matched rats and in the
non-C-peptide treated STZ-D rats, whereas in the STZ-D
rats treated with C-peptide it was 17.4 6 4.7 nmol/liter.
At the end of the acute experiments, the plasma glucose
concentration as measured with the glucose oxidase
method was 6.8 6 0.3 mmol/liter in the control normal
group, 26.2 6 1.6 mmol/liter in the STZ-D group and
28.5 6 1.8 mmol/liter in the STZ-D C-peptide group.
In the additional experiments, the hyperfiltration in
STZ-D rats was again normalized by infusion of C-peptide,
whereas infusion of the scrambled peptide had no effect in
this respect (Fig. 5).
Fig. 1. Mean values (6 SEM) of glomerular filtration rate (GFR) before
and during glycine infusion. Symbols are: (E–E) normal group, N 5 5;
(—) STZ-D group, N 5 11; (f. . . f) STZ-D C-peptide group, N 5 6.
*P , 0.05, **P , 0.01 significantly different from basal period. 1P , 0.05,
11P , 0.01 indicate significant differences between the STZ-D group and
the normal group.
Fig. 2. Mean arterial blood pressure (MAP) before and during glycine
infusion. Symbols are: (E–E) normal group, N 5 5; (—) STZ-D group,
N 5 11; (f. . . f) STZ-D C-peptide group, N 5 6. *P , 0.05, significantly
different from basal period.
Fig. 3. Mean values (6 SEM) of urine flow rate and urine osmolality
before and during glycine infusion. Symbols are: (E–E) normal group,
N 5 5; (—) STZ-D group, N 5 11; (f. . . f) STZ-D C-peptide group,
N 5 6. *P , 0.05, **P , 0.01 significantly different from basal period.
1P , 0.05, 11P , 0.01 indicate significant differences between the STZ-D
groups and the normal group.
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DISCUSSION
In the present study, the rat diabetic model was selected
to create renal changes similar to those found in the early
phase of type 1 diabetes in humans, that is, glomerular
hyperfiltration and increased urinary albumin excretion
[11]. To study the effect of C-peptide more specially,
insulin treatment was avoided, as insulin itself has been
found to suppress, direct or indirect, the spontaneous
hyperfiltration occurring at the early stage of diabetes in
rats [5, 12]. Therefore, by using an STZ dosage 30% lower
than the usual one, a less severe diabetic model was
established. However, all the rats developed classical dia-
betes with polydipsia, polyuria, polyphagia, failure to gain
weight, and hyperglycemia (Table 1). Furthermore, they
exhibited glomerular hyperfiltration with inhibition of RFR
(Figs. 1 and 5) and increased urinary albumin excretion
(Results section).
The renal functional reserve has been assessed clinically
and experimentally by other authors in order to evaluate
the occurrence of hyperfiltration under conditions such as
following partial loss of functional nephrons [13], hyperten-
sion [14, 15], and diabetes mellitus [5, 16]. However, in the
case of diabetic mellitus the loss of renal functional reserve
might also be related to the morphological changes, as
renal hypertrophy in experimental diabetes can be seen
regularly 72 hours after injection of streptozotocin [17]. In
the present study, C-peptide infusion reduced the initial
phase of hyperfiltration before glycine challenge and hence
partly restored the response to the glycine challenge with a
35% increase in GFR (P , 0.05; Fig. 1). The renal
functional reserve was not fully restored during C-peptide
infusion to the level of the non-diabetic controls. The
reason might be due to the hyperglycemic state in the
diabetic rats and/or the fact that the rats were only treated
with C-peptide for a short time period. Moreover, though
infusion of C-peptide itself did not alter the initial MAP, it
restored the MAP response to glycine (Fig. 2). The fact that
MAP is a product of cardiac output and total peripheral
resistance suggests that C-peptide may have acute hemo-
dynamic effects other than in the kidneys. In particular, it
has recently been demonstrated that C-peptide has the
capacity to increase forearm blood flow and decrease
vascular resistance under both basal and exercise condi-
tions in patients with type 1 diabetes [18]. In the present
study, neither blood flow or cardiac output were measured.
It is therefore difficult to speculate about the further details
of these results. Further studies have to be performed to
bring light over these questions. However, it may be of
interest to note that C-peptide appears to stimulate cardiac
function by increasing left ventricular ejection fraction
(15%) in patients with type I diabetes mellitus [19]. The
difference found in basal MAP (NS, not significant) be-
tween the diabetic and non-diabetic rats, is unclear. This
could be due to the hyperglycemia which directly, or
indirectly, may cause a mild dehydration (not measured).
Although this experimental model is not comparable in
every detail with type 1 diabetes in humans, our results are
in good agreement with observations in young patients with
type 1 diabetes [7, 8]. The effects of C-peptide seem to be
of specific origin, since the control “scrambled peptide” had
no effect (Fig. 5). Furthermore, since no difference in
plasma glucose concentration was found between the dia-
betic rats treated with and not treated with C-peptide, the
effects of C-peptide on GFR are clearly direct, rather than
secondary to a change in blood glucose. This hypothesis is
supported by a recently published study by Ido et al [20]
who found that C-peptide improves vascular and neural
function in diabetic rats, independent of glucose levels, and
no effects were seen in non-diabetic rats. They also found
that the improved function was lost if the amino acid
sequence was scrambled. However, peptides with all-D-
amino acids and one with a reversed sequence still had
effects on granular vasculature permeability. These later
findings are puzzling and further investigations are needed
to evaluate the nature of the specificity of C-peptide.
As we did not have access to rat C-peptide, and the fact
that human C-peptide has been shown to have effects in
STZ diabetic rats on vascular and neural function [20] and
on glucose utilization [21], the present study was performed
with a human C-peptide. In consideration of the species
Fig. 4. Mean values ( 6 SEM) of sodium excretion rate (UNaV˙) and
potassium excretion rate (UKV˙) before and during glycine infusion.
Symbols are: (E–E) normal group, N 5 5; (—) STZ-D group, N 5 11;
(f. . . f) STZ-D C-peptide group, N 5 6. *P , 0.05, **P , 0.01
significantly different from basal period. 1P , 0.05, 11P , 0.01 indicate
significant differences between the STZ-D groups and the normal group.
MP , 0.05 indicate significant differences between the C-peptide treated
and non-C-peptide treated STZ-D groups.
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difference in C-peptide, the dosage used was higher than
that in the earlier human studies [7, 8]. The results of
radioimmunoassay showed that the plasma levels of human
C-peptide in the STZ-D C-peptide group were about
twenty times higher than those found in humans. The
chosen dosage of C-peptide was based on the observation
by Ido and co-authors that when administered to rats,
human C-peptide had to be given in a higher dosage than
rat C-peptide in order to obtain comparable results [20, 22].
The STZ-D rats also displayed much higher total protein
leakage both under conscious conditions and during anes-
thesia as compared with normal rats. A 90-min infusion of
C-peptide reduced the total protein leakage by 70% in
STZ-D rats (Table 1 and data in the Results section).
Although different methods have been used for protein
analysis, the present data confirm the clinical observation
that C-peptide can reduce urinary albumin excretion [8].
Since we did not have access to a method measuring
urinary albumin, we determined total protein excretion
instead. The difference found in total protein excretion
between the data from the metabolic cages and the final
renal clearance studies in anesthetized animal could theo-
retically be due to protein contamination from food and
feces during urine collection in the metabolic cages and an
influence of anesthesia. A contamination was not possible
during the final clearance studies, since the urine samples
were collected from a catheter placed directly in the
bladder. Thus, the reduced protein excretion found during
the final clearance periods, in the C-peptide treated STZ
diabetic rats, is probably due to an effect of C-peptide on
glomerular capillary permeability.
High intraglomerular capillary pressure has been as-
sumed to be a primary cause of proteinuria associated with
diabetes mellitus. The rapid reduction of protein excretion
during the infusion of C-peptide may have been due to a
reduction of intraglomerular pressure [9]. This would fit
well with the observed reduction in GFR. However, it
cannot be excluded that the tubular reabsorption of protein
may also have been altered. Further, it is possible that
C-peptide affects the perm-selectivity of renal capillaries.
Again, this must be a consequence of a specific effect of
C-peptide, since it could not be mimicked by the “scram-
bled peptide” (Fig. 5). It has been proposed that albumin-
uria reflects a more generalized vascular dysfunction, in-
volving capillaries of the glomerulus and retina and the
intima of large vessels [23]. This idea is supported by the
finding that C-peptide administration caused a decrease in
the leakage of fluorescein across the blood-retinal barrier
[8]. In any event, further studies need to be conducted in
order to obtain a better understanding of the mechanisms
involved.
The STZ-D rats showed a slightly reduced daily urinary
sodium to potassium ratio two weeks after the onset of
diabetes (Table 1). Also, during the acute experiments
these rats displayed an impaired kaliuretic, but not natri-
uretic, response to glycine challenge (Fig. 4). These results
may imply the presence of relative sodium retention in the
STZ-D rats [24]. If so, C-peptide seems to have the ability
to enhance sodium excretion and thus increase the sodium
to potassium excretion ratio (Fig. 4). This needs to be
confirmed by further research.
The facts that increased renal capillary permeability is
often found in insulin-dependent diabetic patients and that
even vigorous insulin treatment, if given alone, is not
sufficient to prevent nephropathy, have prompted investi-
gations of the complementary role of C-peptide in diabetes
treatment. It is concluded that in the present model,
C-peptide has beneficial effects in reducing protein leakage
and hyperfiltration and improves the renal functional re-
serve in diabetic rats. The observed effects of C-peptide on
the kidney do not seem to be unspecific events caused by
hypoglycemia and/or circulating levels of a highly charged
peptide.
This study also shows that this animal model can be used
Fig. 5. The mean ( 6 SEM) glomerular
filtration rate (GFR) in the STZ-D group (–
, N 5 5), the STZ-D C-peptide group (f–f,
N 5 6) and the STZ-D scrambled C-peptide
group (M–M, N 5 5). The arrow indicates the
start of infusions with either C-peptide or
scrambled C-peptide. *P , 0.05, **P , 0.01
compared with the STZ-D group.
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for the further investigations concerning the mechanisms
underlying the effects of C-peptide.
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APPENDIX
Abbreviations used in this article are: FITC-inulin, fluorescein isothio-
cyanate labeled inulin; GFR, glomerular filtration rate; MAP, mean
arterial blood pressure; RFR, renal functional reserve; STZ-D, strepto-
zotocin-induced diabetes; UKV˙, potassium excretion rate; UNaV˙, sodium
excretion rate.
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